MLB notebook: Red Sox, Rodriguez agree to one-year, $8.3 million deal to avoid arbitration – pressherald.com
Posted: December 6, 2020 at 7:59 am
Eduardo Rodriguez and the Boston Red Sox agreed to a one-year, $8.3-million contract for 2021, according to multiple reports on Tuesday.
The $8.3 million salary is the same the left-handed starter earned in 2020. The Red Sox beat Rodriguez at a salary arbitration hearing before the 2020 season when they filed at $8.3 million and Rodriguez filed for $8.675 million. The two sides avoided salary arbitration this offseason.
Rodriguez who is eligible for free agency after the 2021 season didnt pitch in 2020 because of myocarditis (inflammation of the heart), an after-effect of COVID-19. Rodriguez tested positive for COVID-19 before flying to Boston for summer training camp in early July. Tests in Boston revealed myocarditis. Rodriguez said he experienced every symptom of COVID.
I feel like I was 100 years old, Rodriguez said in July. My body was tired all the time. Throwing up. Headaches. Like I said, all the symptoms.
Rodriguez began throwing again in November after a lengthy recovery. He was Bostons top starter in 2019 and finished sixth in the American League Cy Young voting, going 19-6 with a 3.81 ERA and 1.33 WHIP in 34 starts.
The deadline for MLB teams to tender 2021 contracts to their pre-arbitration and arbitration-eligible players is Wednesday at 8 p.m. Boston has five other arbitration-eligible players Rafael Devers, Matt Barnes, Ryan Brasier, Kevin Plawecki and Austin Brice on its 40-man roster.
INDIANS-MARLINS: Cleveland sold side-arm reliever Adam Cimber to the Marlins for $100,000, and Miami designated right-hander Jos Urea for assignment.
Urea, the Marlins Opening Day starter in 2018 and 2019, spent six seasons with the Marlins and had been with them longer than any other active player. He went 0-3 with a 5.40 ERA in five starts last season, when he had a $3.75 million salary and earned $1,388,889 in prorated pay. He had been projected for a salary of about $4 million for 2021.
Cimber went 0-1 with a 3.97 ERA in 14 games this past season for Cleveland, which acquired the right-hander in 2018 from the San Diego Padres in the deal that brought All-Star closer Brad Hand to the Indians. The 30-year-old Cimber went 6-7 with a 4.30 ERA in 110 appearances with the Indians over 2 1/2 seasons. He was 6-3 in 2019, when he pitched in 68 games.
INDIANS: Rookie reliever Cam Hill underwent surgery on his right wrist after being involved in a car accident in Tulsa, Oklahoma.
Hill shared details of the incident on his Instagram account, saying he was very blessed to only bang up my wrist. Surgery went really well, most importantly the others involved in the accident were all okay.
Hill also posted a photo of him recovering in his hospital bed with his right arm heavily bandaged. He gave a thumbs up with his left hand.
Cleveland said Dr. Brian Chalkin, a hand specialist, operated Monday night on the right-handers lunate bone, located in the mid-carpal joint. The team said surgery went as expected and that it does not have any details yet on Hills rehab or when he might be able to pitch.
Hill made his major league debut with the Indians on July 26 and got his first save two days later against the Chicago White Sox. The 26-year-old went 2-0 with a 4.91 ERA in 18 games with Cleveland.
He made one postseason appearance, allowing three runs in Game 1 of the wild-card series against the New York Yankees.
HALL OF FAME Manager Tom Lasorda has been moved out of intensive care, although he remains hospitalized in Southern California.
Los Angeles Dodgers spokesman Steve Brener said that the teams 93-year-old former manager is doing rehab at the hospital in Orange County. Lasorda has been hospitalized since Nov. 8, although the team didnt make it public until a week later.
Lasorda attended the teams Game 6 victory over the Tampa Bay Rays on Oct. 27 in Texas that clinched the Dodgers first World Series title since 1988.
Lasorda had a record of 1,599-1,439 while managing the Dodgers from 1976-96, guiding them to World Series championships in 1981 and 88. The franchise won four National League pennants and eight division titles under Lasorda. He had a heart attack in June 1996 and retired from managing the Dodgers the following month.
ATHLETICS: Right-hander Burch Smith agreed to a $705,000, one-year contract a day before Wednesdays deadline for teams to offer deals to unsigned players on their rosters.
Smith went 2-0 with a 2.25 ERA and a save in six outings spanning 12 innings for Oakland but was lost for the season in mid-August because of a strained forearm on his pitching side. The As missed his presence in the bullpen as they won the AL West and the wild-card round against the Chicago White Sox before losing to the rival Astros in the AL Division Series.
Also Tuesday, catcher Francisco Pena received a minor league contract. He would earn $600,000 while in the majors if added to the 40-man roster.
METS: New York reached its first agreement with a free agent since Steven Cohen bought the team, a deal with 31-year-old right-hander Trevor May, a person familiar with the negotiations told The Associated Press.
May had a 3.86 ERA in 24 relief appearances for the Minnesota Twins last season, striking out 38 and walking seven in 23 1/3 innings while allowing 20 hits with a career-high fastball velocity averaging 96.66 mph. He earned $816,667 in prorated pay from a salary of $2,205,000.
May had spent all six big league seasons with the Twins, going 23-21 with a 4.44 ERA in 26 starts and 189 relief appearances.
He made 16 starts in 2015, going 8-9 with a 4.00 ERA over 48 appearances. May had Tommy John surgery on March 22, 2017, and returned to the major leagues on July 31, 2018.
May figures to join a bullpen that includes Edwin Diaz, Dellin Betances, Jeurys Familia, Brad Brach and Jacob Barnes.
New Yorks front office is being run by Sandy Alderson, who returned to the Mets as team president on the day that Cohen completed his $2.42 billion purchase from the Wilpon and Katz families.
DRUG TESTS: Major League Baseballs number of drug tests dropped sharply during the novel coronavirus pandemic.
There were 3,733 urine samples and 412 blood samples for human growth hormone testing collected during the year ending with the World Series, independent program administrator Thomas M. Martin said in his annual report. That was down from 9,332 urine samples and 2,287 blood samples in the year ending with the 2019 World Series.
The lower testing numbers were a result of the COVID-19 pandemic as well as the extended closure of the WADA-accredited anti-doping laboratory in Montreal, Martin wrote.
Spring training was interrupted in mid-March and the start of the regular season was delayed from late March until late July. Each teams schedule was cut from 162 games to 60.
There were 10 positive tests for performance-enhancing substances: two for Stanozolol (New York Mets second baseman Robinson Cano and free agent pitcher Victor Alcantara), five for Boldenone (Houston pitcher Francis Martes, Pittsburgh utilityman Pablo Reyes, Arizona infielder Domingo Leyba, Cleveland pitcher Emmanuel Clase and Pittsburgh pitcher Edgar Santana) and three for Dehydrochlormethyltestosterone (DHCMT) (Colorado pitcher Justin Lawrence, Washington catcher Tres Barrera and Houston pitcher Kent Emanuel).
Ninety-one therapeutic use exemptions were granted, 90 for Attention Deficit Hyperactivity Disorder and one for Hypersomnia. That was down from 94 for the previous year, which included 90 for ADHD and one each for Hypersomnia, Hypogonadism and kidney disease.
Exemptions for hyperactivity disorder had ranged from 105-119 annually from 2008-16, prompting some to criticize their issuance as too lenient.
Previous
Next
Read this article:
MLB notebook: Red Sox, Rodriguez agree to one-year, $8.3 million deal to avoid arbitration - pressherald.com
- Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr... - UroToday - February 11th, 2021
- Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News - Jumbo News - February 11th, 2021
- The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law - February 3rd, 2021
- Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday - February 3rd, 2021
- Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX... - January 29th, 2021
- Male Hormone Replacement Therapy And The Side Effects - Nerd's Magazine - January 29th, 2021
- New York Medical and Life Sciences: Year in Review 2020 - JD Supra - January 29th, 2021
- Male menopause: symptoms, diagnosis and treatment - Netdoctor - January 29th, 2021
- Freeman: 'Pressure to Succeed' Led to Testosterone Order - Medscape - January 27th, 2021
- Hormone Replacement Therapy Market Growth Analysis,Size,Insight,Share And Outlook By 2027 Pfizer, AbbVie, Novo Nordisk NeighborWebSJ - NeighborWebSJ - January 27th, 2021
- Male Hypogonadism Therapy Market to Witness Massive Growth During 2021-2027 | Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - January 25th, 2021
- Male Hypogonadism Therapy Market and Ecosystem by Production, Prospects, Consumption, Cost Structure, Competitive Landscape - Jumbo News - January 25th, 2021
- What is Harvey Prices disability Prader-Willi Syndrome? - The Sun - January 25th, 2021
- The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% - NeighborWebSJ - January 19th, 2021
- Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo... - January 19th, 2021
- Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for... - January 19th, 2021
- Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With... - January 12th, 2021
- Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,... - January 9th, 2021
- The Anabolic Steroids Market to sharpen in the next decade - The Monitor - January 9th, 2021
- Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News - December 24th, 2020
- Male Hypogonadism Therapy Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2026 - Cheshire Media - December 6th, 2020
- Male Hypogonadism Market is Expected to Thrive at Impressive CAGR by 2026 & Top Key Players are Astrazeneca Plc., Merck& Co. Inc.,... - December 6th, 2020
- Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for M... - UroToday - December 6th, 2020
- Prader-Willi Syndrome Facts: Causes, Diagnosis, Treatments and Prognosis - Gilmore Health News - December 6th, 2020
- Male Hypogonadism HRT Treatment Market 2020-28 booming segments, latest trends and analysis with Merck & Co, Allergan, Endo International,... - December 6th, 2020
- Impact of Covid-19 on Testosterone undecanoate Market is slated to grow rapidly in the forthcoming years with Key Players Bayer AG, Endo... - November 28th, 2020
- Estrogen in men: Symptoms of high and low levels, and more - Medical News Today - November 11th, 2020
- Aytu BioScience to Present at the Jefferies 2020 Virtual London Healthcare Conference Wednesday, November 18 at 1:45pm ET - Stockhouse - November 11th, 2020
- Global Testosterone Replacement Therapy Market 2020 : Industry Analysis by Top Countries Data Definition, Size, Share, Segmentation and Forecast data... - November 11th, 2020
- Male Hypogonadism Therapy Market Forecast to 2027: Top Companies, Trends & Growth Factors and Trend Forecast to 2027 - TechnoWeekly - November 5th, 2020
- The Male Hypogonadism Market To Slither Amidst Covid-19, To Pick Up Pace Post-Covid-19, Reach US$ 3300 Mn - The Think Curiouser - November 5th, 2020
- Global Hypogonadism Drug Market Business Share, Industry Size and Future Investment Opportunities by 2026||ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly... - November 5th, 2020
- Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020 - Press Release - Digital... - November 5th, 2020
- Global Hormone Replacement Therapy Market Recent Trends, Development, Growth and Forecast 2020-2027 - Eurowire - November 5th, 2020
- Andropause: Not the same as menopause but needs to be addressed - The Star Online - October 28th, 2020
- Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) for the... - October 28th, 2020
- Hormone Replacement Drugs Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026|Eli Lilly, Pfizer, AbbVie - Eurowire - October 28th, 2020
- The Anabolic Steroids market to go the reverse transversal way in the next decade - The Think Curiouser - October 25th, 2020
- EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi and Submits Market... - October 25th, 2020
- Male Hypogonadism Therapy Market is Booming Worldwide By Top Key Players: Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - October 13th, 2020
- Hormone Replacement Therapy Market Size, Trends, Growth, Key Companies, Forecast by 2026|Eli Lilly, Pfizer, AbbVie - Weekly Wall - October 13th, 2020
- Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year - BioSpace - October 10th, 2020
- Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020 - Yahoo Finance - October 10th, 2020
- Sperm Take Up to 3 Years to Recover After Anabolic Steroids - Medscape - October 4th, 2020
- Covid-19 could lower testosterone levels and libido in men - heres what the new study found - Shields Gazette - October 4th, 2020
- Testosterone Replacement Therapy Market 2020 Global Industry Sales, Industry Analysis with Top Countries Data, Share, Trends, Market Demand, Revenue,... - October 4th, 2020
- Treatment of the infertile couple - Contemporary Obgyn - October 4th, 2020
- Testosterone boosters: Uses and effectiveness - Medical News Today - September 22nd, 2020
- Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020 - Yahoo Finance - September 18th, 2020
- H.C. Wainwright Reiterated Lipocine Inc. [LPCN]. What else is Wall St. saying? - The DBT News - September 3rd, 2020
- Hormone Replacement Therapy Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the... - September 3rd, 2020
- Male Hypogonadism Market Estimated to be Driven by Innovation and Industrialization 2017 2026 - The News Brok - August 24th, 2020
- Male Hypogonadism Therapy Industry 2020 Market Size, Share, Price, Trend And Forecast To 2026- Industry Growth Insights - The Scarlet - August 24th, 2020
- Male Hypogonadism Market : Extensive Analysis of Key Segments of the Industry and Emerging Growth Factors with Current Trends and Future Estimations -... - August 24th, 2020
- COVID-19 Impact On Hormone Replacement Therapy Market Size, Status And Forecast 2020-2026 - Galus Australis - August 14th, 2020
- Male Hypogonadism Therapy Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast to 2027... - August 13th, 2020
- UB study finds testosterone therapy can lead to remission in men with Type 2 diabetes - UB Now: News and views for UB faculty and staff - University... - August 5th, 2020
- Male Hypogonadism Market 10-Year Market Forecast and Trends Analysis Research Report2017 2026 - The Daily Chronicle - August 4th, 2020
- UB diabetes expert's research shows testosterone therapy can lead to remission in men with Type 2 diabetes - UB News Center - July 31st, 2020
- Hormon replacement therapy Market Growth, Opportunities and Updated Business Strategies|Bayer Pharma - PharmiWeb.com - July 31st, 2020
- What are COVID-19 Impact on Male Hypogonadism Market? & what are Major Drives Which Boost Market Even In Outbreak? - WOLE TV - July 31st, 2020
- Testosterone Replacement Therapy and Its Potential Mental Health Benefits to Men - Press Release - Digital Journal - July 31st, 2020
- Global Testosterone Cypionate Market (Covid-19 Impact) Expected to Witness a Sustainable Growth over 2026 - Market Research Correspondent - July 31st, 2020
- Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration - BioSpace - July 31st, 2020
- What is Male Menopause? Heres everything you need to know about andropause - PINKVILLA - July 26th, 2020
- North America Hormone Replacement Therapy Market: Demand, Share, Size, Industry Trends, Analysis and Forecast during 2020-2025 - Jewish Life News - July 3rd, 2020
- North America Hormone Replacement Therapy Market: Share, Industry Trends, Price, Size, Demand and Forecast to 2020-2025 - 3rd Watch News - July 3rd, 2020
- Testosterone undecanoate Market 2020 | What Will Be the Market Size and the Growth Rate Analysis by 2025? - Cole of Duty - July 1st, 2020
- Advancements in treatments in healthcare is boosting the Human Chorionic Gonadotropin (HCG) Market - Day Web Chronicle - July 1st, 2020
- Global Hormone Replacement Therapy Market 2020 Research by Business Analysis, Growth Strategy and Industry Development to 2025 - Cole of Duty - July 1st, 2020
- No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - The Gardner News - June 22nd, 2020
- Human Chorionic Gonadotropin (hCG) Market Insights on Growth Trends, Top Players, Types, Applications and Regional Analysis - Personal Injury Bureau... - June 22nd, 2020
- Male Hypogonadism Therapy Market Research Growth by Manufacturers, Regions, Type and Application, Forecast Analysis to 2026 - CueReport - June 20th, 2020
- Emerging Opportunity in Transdermal Testosterone Market with Eminent Key Players and Future Outlook to 2024: AbbVie, Teva, Perrigo, Endo... - June 20th, 2020
- No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - Lexington Dispatch - June 20th, 2020
- Testosterone Gel Market: 2020 Industry Trends, Size, Growth Predictions, Segmentation, Business Statistics, Top Key Players and 2026 Forecast Research... - June 18th, 2020
- Anabolic Steroids Market to Witness Heightened Revenue Growth in the Next Decade - Owned - June 18th, 2020
- Male Hypogonadism Therapy Market Business Analysis 2020 by Leading Industrial Source, Statistics, Gross Margin, Upstream Analysis, Downstream Analysis... - June 14th, 2020
- QOL and body composition benefits seen with novel oral T treatment - Urology Times - June 14th, 2020
- Novel oral testosterone therapy shows liver health benefits - Urology Times - June 14th, 2020